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Abstract Advances in renal transplantation management
have proven to be beneficial in improving graft and patient
survival. One of the properties of a well-functioning renal
allograft is the secretion of adequate amounts of the
hormone erythropoietin to stimulate erythropoiesis. Post-
transplantation anemia (PTA) may occur at any point in
time following transplantation, and the cause is multi-
factoral. Much of our understanding of PTA is based on
studies of adult transplant recipients. The limited number of
studies that have been reported on pediatric renal transplant
patients appear to indicate that PTA is prevalent in this
patient population. Erythropoietin deficiency or resistance
is commonly associated with iron deficiency. An under-
standing of the risk factors, pathophysiology and manage-
ment of PTA in the pediatric renal transplant population
may provide guidelines for clinicians and researchers in the
pursuit of larger prospective randomized control studies
aimed at improving our limited knowledge of PTA.
Recognition of PTA through regular screening and evalu-
ation of the multiple factors that may contribute to its
development are recommended after transplantation.
Keywords Erythropoietin.Erythropoiesis-stimulating
agents.Iron deficiency.Posttransplantation anemia.Renal
transplantation
Introduction
Renal transplantation is considered to be the optimal renal
replacement therapy for pediatric patients with end-stage
renal disease (ESRD). Advances in the management of
renal transplantation, particularly those related to immuno-
suppression therapy, have led to an increase in patient and
graft survival. A well-functioning renal allograft is able to
synthesize adequate amounts of erythropoietin (EPO) for
erythrocyte synthesis. However, in patients with suboptimal
graft function, posttransplantation anemia (PTA) may occur
at any time in the posttransplant period, which may cause
tissue hypoperfusion and hypoxia leading to cardiovascular
morbidity and even potential graft loss. In this review, PTA
will be defined and its prevalence determined. EPO
production posttransplantation will also be discussed. Early
recognition of possible risk factors to PTAwhich may lead to
theappropriate interventionthat will optimizethefunctionof
the newly transplanted kidney will be highlighted.
It can be said that the development of anemia in the
posttransplant setting has received less attention than the
occurrence of anemia in the chronic kidney disease (CKD)
and dialysis patients. It can also be argued that PTA is an
issue that have been overlooked since the focus of renal
transplantation is on the prevention of rejection and the
achievement of good renal function. However, with the
improvement in allograft and patient survival rates, there
has been a shift in emphasis towards the control of
cardiovascular risk factors, which are relevant to the
survival of the transplant patient.
Posttransplantation anemia may affect the patient’s
quality of life (QOL). Kawada et al. tested the administra-
tion of recombinant human EPO (rHuEPO-ad) and its
positive impact on QOL [1]. In this study, the physical and
mental QOL of their patients before and after rHuEPO-ad
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score (PSC) and a mental summary score (MSC), respec-
tively, using a 36-item short form (SF-36) which is an
international questionnaire used to analyze the QOL.
Before rHuEPO-ad, posttransplant patients had a preserved
MSC but impaired PSC. The administration of rHuEPO for
6 months increased their hemoglobin (Hb), which was
accompanied by an improvement of the PSC. Gheith et al.
determined the impact of PTA on long-term patient graft
survival and showed that chronic allograft nephropathy was
significantly higher in the anemic group [2]. A 12-month
PTA has been found to be associated with subsequent graft
loss and patient mortality [3]. Furthermore, PTA is
associated with an increased risk of congestive heart failure
and left ventricular hypertrophy [4].
The definition of PTA varies among different studies and
guidelines and is mostly based on the appropriate hemoglo-
bin and hematocrit level for age and sex [e.g., <13 g/dL for
men and <12 g/dL for women; with hematocrit level of >2
standard deviations (SD) below published means for age]
and/or EPO dependency [5–10]. This definition is mainly
applicable to adult transplant patients. In the pediatric
population, the diagnosis of anemia is made when the
observed hemoglobin concentration is <5th percentile of
normal when adjusted for age and sex.
The reported prevalence of PTA, mainly in the adult
population, varies among studies [6–17]. In a study by
Turkowski-Duhem et al., PTAwas defined as a hemoglobin
level of <13 g/dL for men and <12 g/dL for women, with a
prevalence of 35.5% (32 patients) and 25% (23 patients) at
6- and 12-months posttransplantation, respectively [6]. In a
retrospective cohort study of 162 pediatric transplant
recipients, Yorgin et al. [7] defined anemia as a hematocrit
level of >2 SD below published means for age or as EPO
dependency to maintain a normal hematocrit level. The
study showed that 67% of the recipients were anemic at the
time of transplant and that the prevalence increased to
84.3% in the first month posttransplant. From 6 to
60 months posttransplant, the prevalence of anemia
remained high at 64.2–82.2% [7]. In another retrospective
study, Mitsnefes et al. found out that anemia was present in
59 of 231 (25.5%) of their pediatric patients 1 year after
renal transplantation [8]. In this study, anemia was defined
as Hb <11 g/dL, as used in the Kidney Disease Outcomes
Quality Initiative (KDOQI) Clinical Practice Guidelines for
Anemia of Chronic Kidney Disease [9]. It was suggested
that the increased incidence of PTA is related to modern
immunosuppressive therapy and that it is more likely a
markerofallograftdysfunctionratherthanitscause.Kausman
et al. [10] studied 50 pediatric renal transplant recipients and
found that the overall prevalence of PTAwas 60%, including
30% who were severely anemic. In this study, anemia was
defined as Hb <11 g/dL (age 2–6 years), Hb <11.5 g/dL
(age >6–12 years), or Hb <12 g/dL (age >12 years), and
severe anemia was defined as Hb <10 g/dL [10].
Risk factors for posttransplantation anemia
Table 1 lists the many risk factors for PTA. As can be seen,
some of these (e.g., inadequate ESRD management,
insufficient diet resulting to iron, vitamin B12, folate
deficiency, and drug-induced factors) are shared with
patients with CKD who do not undergo transplantation.
The use of immunosuppressive agents [e.g., tacrolimus
(TC), azathioprine (AZA), mycophenolate mofetil
(MMF)] with direct antiproliferative effects on the bone
marrow is the most common risk factor for PTA [6, 10,
11, 16]. Peter et al. compared the rate of anemia in
pediatric patients treated with TC vs. cyclosporine (CsA)
[18]. Eighty-five children on CsA therapy were compared
with ten patients on TC. A matched-pair analysis for
creatinine clearance was performed, revealing equal
values in both groups. CsA-treated patients showed a
clearance of 48 mL/min/1.73 m
2, while TC-treated patients
hada clearanceof46mL/min/1.73m
2. Hemoglobin was 10.3
and 10.4 g/dL in the TC- and CsA-treated patients,
respectively, and there was no significant difference in the
degree of anemia between the TC- and CsA-treated children.
Among those children with functioning renal allografts, there
was a positive correlation between the hemoglobin level and
creatinine clearance.
Other common causes of PTA are blood loss, either
secondary to the transplant surgery or multiple phlebotomy
postoperatively or during outpatient follow-up for monitor-
ing of the renal allograft, and an insufficient diet that results
in iron, vitamin B12, and folate deficiency. Rejection
episodes also contribute to PTA [19–21]. To increase our
understanding of the molecular events underlying anemia in
acute rejection, Chua et al. [22] analyzed the gene
expression profiles of peripheral blood lymphocytes
(PBL) from four pediatric renal allograft recipients with
acute rejection and concurrent anemia using DNA micro-
arrays. An ‘erythropoiesis cluster’ of 11 down-regulated
genes was identified in these anemic rejecting patients that
was involved in hemoglobin transcription and synthesis and
in iron and folate binding and transport. Additionally, some
alloimmune response genes, including immunoglobulins,
were simultaneously down-regulated [22]. Kidney allograft
recipients may also be particularly susceptible to anemia in
the immediate postoperative period for several reasons.
First, ESRD anemia management may not have been ideal.
Second, an impaired EPO production or release by the
transplanted kidney may occur secondary to a delayed graft
function. Finally, if chronic EPO therapy is stopped, the
decrease in hemoglobin level is more marked and the
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25]. Other risk factors include infections, and a unique
example of infection is pure red cell aplasia due to infection
with parvovirus B19, which exhibits tropism for erythro-
cyte precursors, resulting in maturation arrest at the
pronormoblast stage [26, 27]. Cytomegalovirus can directly
inhibit hematopoiesis by involving not only bone marrow
stroma, but also hematopoietic precursor and stem cells
[28, 29]. An additional risk factor for PTA is a repeat renal
allograft. Hemoglobin levels have been found to be higher
in patients who received a first kidney transplant (13.2±
1.9 g/dL) than in those who received a second (12.8±
1.9 g/dL) or third transplant (12.7±2.1 g/dL) [11].
Advanced donor age (>60 years) is another risk factor
[11]. There are a number of theoretical reasons why an
EPO-resistant state may develop after renal transplantation.
Some are associated with CKD, including iron deficiency,
ongoing hyperparathyroidism, and chronic inflammation [30,
31]. The use of angiotensin converting enzyme (ACE)
inhibitors and angiotensin II receptor antagonists has been
associated with PTA [11, 16, 32]. One explanation that has
been proposed for the development of anemia associated
with ACE inhibitors is the possible lower production of EPO
associated with impaired renal blood flow [33]. Another
proposed explanation is a possible decrease in renal oxygen
consumption determined by sodium absorption in the
proximal tubules that is regulated by angiotensin II [34, 35].
What happens to EPO production and erythropoiesis
posttransplantation?
Erythropoietin is mainly produced by the peritubular
capillary endothelial cells in the kidneys, with a small
contribution by the liver (<10%). After a successful renal
transplant, EPO levels usually normalize, and active
erythropoiesis ensues, creating a functional depletion of
iron [36]. However, PTA may occur due to EPO resistance,
which is characterized by high serum EPO levels relative to
the hemoglobin value, or by EPO deficiency, which is
characterized by low levels of both EPO and hemoglobin.
In adult studies with immediate graft function, serum EPO
levels may be detected as early as the first to third
posttransplant day, remain elevated for 9–15 days after
transplantation,and decreasethereafter[37]. This observation
may be less applicable in our current transplant population
because of the widespread use of erythropoiesis-stimulating
agents (ESAs).
In recipients with delayed graft function, a biphasic
pattern is observed, with a first peak of EPO occurring 4–
6 days posttransplant that is not associated with reticulocy-
tosisorchangeinthehematocritvalues[38–40]. A lag phase
between the initial rise in serum EPO levels and the onset
of reticulocytosis may be attributed to uremic inhibitors of
erythropoiesis that persist in the immediate posttransplant
period. Low serum EPO levels increase 3–8 days after the
onset of diuresis and well before the serum blood urea
nitrogen and creatinine reach their nadir [37]. EPO
resistance has been partly attributed to the inflammatory
status induced by surgical intervention and to the occur-
rence of infectious complications [41].
Iron deficiency anemia in the posttransplant setting
Iron deficiency anemia is common in the pediatric ESRD
population and after renal transplantation. Iron may be
depleted at the time of renal transplantation because of
Table 1 Risk factors for
posttransplantation anemia
ESRD, End-stage renal disease;
EPO, erythropoietin; ACE,
angiotensin converting
enzyme; HIV, human
immunodeficiency virus
Risk factors for posttransplantation anemia
Immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil, tacrolimus)
Blood losses (during surgery or laboratory procedures)
Inadequate ESRD anemia management prior to transplantation
EPO resistance
Poor EPO production by the transplanted kidney
Sudden discontinuation of chronic EPO treatment posttransplantation
Insufficient diet resulting in iron, vitamin B12, folate deficiency
Drug-induced (e.g., ACE inhibitors, angiotensin-II receptor antagonists)
Rejection episodes
Delayed or impaired graft function
Advanced donor age
Viral infection (e.g., parvovirus B19, cytomegalovirus, Epstein–Barr virus, HIV)
Malignancy or lymphoproliferative disorder
Repeat renal allograft
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dialysis. Female patients are more prone to iron loss with
menstruation. Kausman et al. showed a high rate of iron
deficiency (30%) in 50 pediatric renal transplant recipients
and identified serum iron as the parameter of iron
metabolism associated with anemia [10]. There has been a
debate as to the ideal marker for iron deficiency, particu-
larly for patients requiring ESAs. The most accepted
parameters for iron deficiency include ferritin and transfer-
rin saturation (TSAT) [12, 42]. However, there are no
reported studies regarding the acceptable serum ferritin and
TSAT in the renal transplant population. Newer alternative
markers of iron status, such as reticulocyte hemoglobin
content, percentage of hypochromic red cells, and soluble
transferrin receptor may be of value [43].
At the present time, there are no definitive criteria for
iron deficiency anemia in posttransplant patients, even in
the presence of normal serum creatinine. Thus, the criteria
to define iron deficiency anemia in children with CKD who
are treated with ESAs, namely serum ferritin of <100 ng/mL
and TSAT of <20%, are suggested for the pediatric renal
transplantrecipients[23]. Specific iron-marker cutoffs for the
diagnosis of iron deficiency anemia in children with CKD
not treated with ESAs do not exist. The same is true for
transplant recipients who are not on ESAs.
Approach to posttransplantation anemia management
The high prevalence of PTA rationalizes the use of iron
and ESAs in the posttransplant period, avoiding unnec-
essary blood transfusions among renal transplant recip-
ients. Most of the recommendations on renal PTA
management are based on adult studies with limited
data on the pediatric population [8, 10, 44]. The
European Best Practice Guidelines for Renal Transplanta-
tion recommend treating PTA in the same manner as
anemia in CKD, although there is little evidence to
support this recommendation [45].
The anemia workgroup at the Lisbon Conference on the
Care of the Kidney Transplant Recipient advised initiating
therapyforanemiawhenthehemoglobindropsbelow11g/dL
[25]. According to the 2007 update of the KDOQI Clinical
Practice Guidelines and Clinical Practice Recommendations
for Anemia in CKD, the selected hemoglobin target in
patients receiving ESAs should be in the range of 11.0–
12.0 g/dL and not greater than 13.0 g/dL [46]. Unfortunately,
the optimal hemoglobin to be achieved with anemia therapy
is unknown in the transplant population.
Only a limited number of studies have focused on ESA
therapy in children with PTA. Yorgin et al. [7] reported that
the mean dose of ESA required to effectively treat PTAwas
144±121 units/kg/week, a dose similar to that required to
treat adults. In their study, Mitsnefes et al. [8] were unable
to evaluate the benefits of recombinant EPO therapy due to
the low number of patients who were treated with EPO
during the first year after transplantation. However, they did
observe a more frequent use of EPO in children on TC,
MMF, and prednisone therapy, which strongly suggests that
the increase in PTA is related to the current use of these
newer immunosuppressive agents [8].
Iron deficiency is the most common cause of hypores-
ponsiveness to ESAs, and pharmacological therapy with
either an oral or parenteral iron preparation is recommen-
ded. Iron supplementation should begin via the oral route to
maintaina TSAT >20% and a ferritin level of 100–800 ng/mL
[25]. If oral supplementation is inadequate to maintain these
parameters, parenteral iron should be administered. Vitamin
B12 and folate supplementation may be required if insuffi-
cient levels are noted.
Oral iron is best absorbed if given on an empty stomach
or with vitamin C-containing foods. If ferrous sulfate is
used, the usual adult dose is one 300 mg tablet (containing
60 mg elemental iron) given three to four times daily. The
pediatric dose is 2–6 mg/kg per day of elemental iron given
in two to three divided doses [47, 48]. The side effects of
oral iron therapy include constipation, diarrhea, nausea, and
abdominal pain.
The parenteral administration of iron has been proven to
be safe in pediatric ESRD patients on hemodialysis [49–
53]. Potential side effects associated with intravenous (IV)
iron administration include acute allergic reactions, such as
rash, dyspnea, wheezing, and anaphylaxis. These side
effects are predominantly seen in iron dextran as compared
to the newer generation of IV iron (e.g., sodium ferric
gluconate and iron sucrose) which are associated with less
severe and less frequent adverse reactions [49, 54]. The
cause of these immediate adverse reactions are not
completely understood, but several mechanisms have been
identified, including the direct release of mediators by mast
cells, without stimulation by immunoglobulin E or immune
complexes [55]. Warady et al. recommended that the
starting dose of IV sodium ferric gluconate (SFG) complex
be 1.0 mg/kg, not to exceed 125 mg, with adjustments
made according to TSAT and/or serum ferritin levels [52].
Gillespie et al. analyzed data from 14 pediatric renal
transplant recipients who received SFG for PTA during a
28-month period [56]. Patients received one to six doses of
SFG to yield a total dose of 100–1000 mg or 2.7–23.7 mg/kg.
The largest doses given during a single infusion ranged from
1.9 to 6.4 mg/kg. There was a modest, yet statistically
significant, increase in mean hemoglobin and hematocrit
values, while changes in TSAT and EPO dose were not
statistically significant. Adverse events, including muscle
pain, painatthe siteofinfusion, hypertension, footnumbness,
and dizziness, were reported in three patients. Since IV iron
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require long-term patient adherence, and is relatively safe, its
use may be beneficial for the treatment of severe iron
deficiencyanemiaintransplantrecipients[57]. More recently,
newer IV iron preparations have appeared in the market,
including ferumoxytol and ferric carboxymaltose. These
latest IV iron preparations do not contain a requirement for
a test dose, and a much higher dose of iron can be delivered
as a single administration.
To decreasetheincidence ofirondeficiencyanemiaamong
transplant recipients, their diet should contain iron-fortified
whole grains, seafood, dried beans, lean red meats, liver,
spinach, and dried fruits such as raisins, prunes, dates, and
apricots. There are two forms of dietary iron— heme and
nonheme iron. The former is commonly found in animal food
sourcesandisbetterabsorbedthanthelatter,whichisfoundin
plant food sources. The recommended dietary allowances for
iron for infants and children are the following: for infants 7–
12 months old, males (M) and females (F)=11 mg/day; for
children ages 1–3 years, M and F=7 mg/day; aged 4–8y e a r s ,
M and F=10 mg/day; aged 9–13 years, M and F=8 mg/day;
aged 14–18 years, M=11 mg/day and F=15 mg/day [58].
Signs of iron deficiency anemia include weakness, slow
cognitive and social development, difficulty in maintaining
body temperature, decreased immune function, and glossitis.
The use of iron supplementation and ESAs should
preclude the need for blood transfusion, which should
be limited to patients with symptomatic anemia or acute
and severe blood loss. Blood transfusions expose a
recipient to soluble and cell-bound antigens, which can
activate the recipient’s immune system, possibly leading
to transfusion complications [59, 60]. Exposure to
alloantigens, in particular leukocytes, can lead to T-cell
activation and proliferation and to increased natural killer
cell function. It can induce humoral immunity, as reflected
by the formation of human leukocyte antigen alloanti-
bodies. Thus, if needed, leukocyte-free blood products are
used to prevent graft-versus-host reactions in transplant
recipients.
Future perspectives
Anemia is fairly common among pediatric renal trans-
plant recipients. Larger prospective and randomized
controlled trials are needed to improve our knowledge
on PTA, in particular the determination of optimum
hematologic status among pediatric renal transplant
recipients. Recognition of PTA through regular screen-
ing and meticulous evaluation of the multiple factors
that may contribute to it are recommended. Clinical
practice guidelines should be developed for the evalu-
ation and management of this unique group of patients.
Questions (answers are provided
following the reference list)
1. In a functioning renal allograft, serum erythropoietin is
detected within:
a. First 72 h posttransplantation
b. Day 4–5 posttransplantation
c. Day 6–7 posttransplantation
d. After 1 week posttransplantation
2. The most accepted parameters for monitoring iron
deficiency anemia are the following:
a. Hemoglobin and ferritin
b. Ferritin and total iron binding capacity
c. Ferritin and transferrin saturation
d. Hemoglobin and transferrin saturation
3. The following are risk factors for posttransplantation
anemia, except:
a. Sudden discontinuation of EPO treatment
posttransplantation
b. Advanced donor age
c. Posttransplant lymphoproliferative disorder
d. Absence of rejection episode
4. The most common cause of unresponsiveness to an
erythropoiesis-stimulating agent is:
a. Use of immunosuppressive drugs
b. Iron deficiency anemia
c. Use of ACE inhibitors
d. Viral infection
5. Based on the Report of the Lisbon Conference on the
Care of the Kidney Transplant Recipient, the therapy
for posttransplantation anemia begins when:
a. Hemoglobin drops below 10.0 g/dL
b. Hemoglobin drops below 11.0 g/dl
c. Hemoglobin drops below 12.0 g/dl
d. Patient becomes symptomatic
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